PCM
MBX

Prelude Capital Management’s MBX Biosciences MBX Stock Holding History

Prelude Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,617
Closed -$178K – 1431
2025
Q2 		$178K Sell
15,617
-24,608
-61% -$251K 0.02% 837
2025
Q1 		$297K Buy
+40,225
New +$425K 0.02% 714

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prelude Capital Management's MBX Position: Q3 2025 in Review

Prelude Capital Management sold out of MBX Biosciences (MBX) in Q3 2025, closing a stake of 15,617 shares — an estimated $178K sold.

Prelude Capital Management first reported a position in MBX in Q1 2025 and held it in 2 quarters. The position peaked at $297K in Q1 2025. 118 funds tracked by Wall St. Rank hold MBX as of Q3 2025.

  • Prelude Capital Management reported no remaining MBX Biosciences position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 15,617 MBX Biosciences shares in Q3 2025, an estimated $178K.
  • Prelude Capital Management first reported a position in MBX Biosciences in Q1 2025 and held it in 2 quarters.
  • Prelude Capital Management's MBX Biosciences position peaked at $297K in Q1 2025.
  • 118 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.